Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 19:e02705.
doi: 10.1002/cbdv.202502705. Online ahead of print.

Toward a Better Understanding of Fatty Acid Amide Hydrolase Inhibition by β-Lactams

Axel Morelle  1   2 , Juhans Dechenne  1 , Joséphine Caruano  1 , Olivia Vander Auwera  1 , Gabriella Barozzino-Consiglio  1 , Catherine Michaux  3 , Giulio G Muccioli  2 , Raphaël Robiette  1
Affiliations

Toward a Better Understanding of Fatty Acid Amide Hydrolase Inhibition by β-Lactams

Axel Morelle et al. Chem Biodivers. .

Abstract

Fatty acid amide hydrolase (FAAH) inhibition holds therapeutic promise by enhancing endocannabinoid signaling. We previously identified β-lactam compounds as reversible and selective hFAAH inhibitors with nanomolar potency. Here, we describe the synthesis of new β-lactam derivatives to evaluate the effect of imide conformational constraints on activity and to eliminate potential metabolic soft spots. Bicyclic derivatives were designed to lock the imide in a syn configuration, but showed reduced potency compared with non-cyclic analogs. Docking studies revealed that this weaker inhibition arises from an altered binding mode within the FAAH active site. In parallel, removal of ester and allyl groups did not affect inhibitory potency. Importantly, the optimized inhibitor enhanced N-acylethanolamine levels in J774 cells, supporting target engagement and suggesting improved metabolic stability. These results provide insights into the mode of action of β-lactam FAAH inhibitors and guide the development of more potent, stable derivatives.

Keywords: FAAH; Inhibitor; β‐lactam.

PubMed Disclaimer

References

    1. A. Romano, M. Friuli, B. Eramo, et al., ““To Brain or Not to Brain”: Evaluating the Possible Direct Effects of the Satiety Factor Oleoylethanolamide in the Central Nervous System,” Frontiers in Endocrinology 14 (2023): 1158287–1159299, https://doi.org/10.3389/fendo.2023.1158287.
    1. N. van Egmond, V. M. Straub, and M. van der Stelt, “Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors,” Annual Review of Pharmacology and Toxicology 61 (2021): 441–463.
    1. J. E. Schlosburg, S. G. Kinsey, and A. H. Lichtman, “Targeting Fatty Acid Amide Hydrolase (FAAH) to Treat Pain and Inflammation,” AAPS Journal [Electronic Resource] 11 (2009): 39–44, https://doi.org/10.1208/s12248‐008‐9075‐y.
    1. K. Ahn, D. S. Johnson, M. Mileni, et al., “Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain,” Chemistry & Biology 16 (2009): 411–420, https://doi.org/10.1016/j.chembiol.2009.02.013.
    1. N. R. Bachur and S. Udenfriend, “Microsomal Synthesis of Fatty Acid Amides,” Journal of Biological Chemistry 241 (1966): 1308–1313, https://doi.org/10.1016/S0021‐9258(18)96775‐X.

LinkOut - more resources